Company Overview and News
2018-10-03 globenewswire - 1
Mechelen, België; 3 oktober 2018, 22.01 CET; gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) kondigt een kapitaalverhoging aan als gevolg van de uitoefening van warrants.
Mechelen, Belgium; 3 October 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.
Stuck in a narrow trading range since mid-August, shareholders are in a wait-and-see mode with Gilead Sciences (NASDAQ:GILD). Yet value investors will be all over this inexpensive stock today. The stock trades at a forward price-to-earnings ratio of 11.9 times. The company also is competing in the generic drug market space for medicines treating hepatitis C, is finding success developing a number of new products, and is not getting left behind in the stock market as the biotechnology sector rebounds.
GILD GLPG ABBV
2018-09-29 seekingalpha - 1
Galapagos NV (NASDAQ:GLPG) had a tough few months, where its stock showed volatility and failed to make any substantial up move. However, the company still retains its long-term viability and the stock maintains its long-term upward momentum as well. The stock first hit the investment radars in 2016 and has shown strong growth since then. We have been bullish GLPG since early 2017.
GILD GLPG GLPG
Mechelen, België; 24 september 2018, 07.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) kondigt de eerste dosering aan in de wereldwijde Fase 2 studie ROCCELLA met S201086/GLPG1972 bij patiënten met artrose in de knie. Galapagos ontvangt hiervoor een mijlpaalbetaling van €9 miljoen van haar samenwerkingspartner Servier.
Mechelen, Belgium, September 24 2018, 07.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the global ROCCELLA Phase 2 trial with GLPG1972/S201086 in knee osteoarthritis patients. Galapagos receives a €9 million milestone payment from its collaboration partner Servier for this achievement.
Mechelen, Belgium, 17 September 2018, 22.01 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today the closing of its underwritten public offering of 2,961,373 American Depositary Shares ("ADSs") at a price of $116.50 per ADS, before underwriting discounts, for gross proceeds of €296.2 million. This includes the full exercise of the underwriters' option to purchase additional ADSs.
GLPG GLPG MS BR
MECHELEN, België, 17 september 2018, 22.01 CET, gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de afronding aan van de onderschreven openbare aanbieding van 2.961.373 American Depositary Shares ("ADSs") voor een prijs van $116,50 per ADS, voor aftrek van de underwriting discounts, voor een bruto-opbrengst van €296,2 miljoen. Dit is inclusief de volledige uitoefening door de underwriters van hun optie om bijkomende ADSs te kopen.
GLPG GLPG MS BR
MECHELEN, België, 17 september 2018, 22.01 CET; gereglementeerde informatie - Galapagos NV (Euronext & Nasdaq: GLPG) kondigt een kapitaalverhoging aan als gevolg van de openbare aanbieding van American Depositary Shares.
Mechelen, Belgium; 17 September 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase as a result of a public offering of American Depositary Shares.
2018-09-17 seekingalpha - 3
XBiotech reported preliminary positive data from an open-label, dose escalation study of Phase 2 trial assessing its bermekimab candidate in moderate to severe atopic dermatitis (AD). On September 13, the share price climbed 28% pre-market on this apparently positive news. However, in spite of two subsequent spikes during the last two days, the share price has not yet fully recovered to its price range before the mid-September slide that wiped off ~50% of its share price between September 6 ($4.
MBRX MOR IRWD REGN AZN MPSYY INCY ARQL GLPG ARDX ACOR AZN MPSYF BIIB XBIT NVS
PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / September 13, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Galapagos NV (GLPG) announced today the initiation of a phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.
MOR MPSYF MPSYY GLPG
2018-09-13 globenewswire - 1
Mechelen, België en Planegg / München, Duitsland; 13 september 2018; 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) en MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) hebben vandaag de start aangekondigd van een Fase 1 overbruggingsstudie voor het onderzoeken van een subcutane formulering van MOR106, een antilichaam in ontwikkeling gericht tegen IL-17C.
MOR MPSYF MPSYY GLPG GLPG
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...